APP 695+1 Antibody (128715) [Alexa Fluor® 488]

• Reactivity: Hu
• Applications: WB, IP
• Clone: 128715
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488

APP 695+1 Antibody (128715) [Alexa Fluor® 488] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human APP695⁺¹ frameshift mutant
  Leu18-Arg336 (predicted)
  Accession # NP_958817
• Specificity: Detects human APP695⁺¹ in Western blots. It recognizes a common epitope present on APP695⁺¹ and APP770 found within the segments L18-R288 or P365-R411 of APP770 (Accession # P05067).
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for APP 695+1 Antibody (128715) [Alexa Fluor® 488]

• AAA;ABETA;ABPP;AD1;alpha-sAPP;Amyloid-beta A4 protein;Amyloid-beta precursor protein;APPI;CTFgamma;CVAP;PN2;PN-II;preA4
• APP695+1

Background

Amyloid precursor protein (APP) is a type I membrane protein with several human isoforms due to alternative splicing. APP770, 751, and 733 contain a Kunitz protease inhibitor (KPI) domain (residue 291‑342) and APP695 does not. APP is a cell surface molecule with many functions. It can be processed proteolytically in two different pathways. In one pathway, beta - and gamma -secretase cleave at the  beta  site between residue 670 and 671 and the gamma site between residue 711 and 714 to produce beta ‑amyloid peptide (A beta 40 and A beta 42), a major component in plaques found in brains of patients with Alzheimer's disease (1). The other pathway involves alpha -secretase that cleaves residues between 687 and 688. It is antiamyloidogenic due to its benign character and the prevention of the A beta peptide formation (2). Soluble APP containing the KPI domain, also referred to as protease nexin II, is a potent inhibitor of serine proteases and may have additional functions. For example, it may regulate the contact face of blood coagulation and limit thrombosis specially in brain due to its localization and coagulation factor XI inhibiting activity (3, 4).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.